Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Balgrist University Hospital | OTHER |
Not provided
Not provided
Not provided
In this project, the aim is to recruit patients with drug resistant epilepsy and those suffering from migraine. Interestingly, patients suffering from epilepsy are also more often reporting to suffer from migraine. The pathobiology is understudied, but it is believed that both etiologies results from brain networks changes. A clinical certified 7T Terra Siemens scanner will be employed to assess in all participants (including healthy controls) how the microstructure differs in disease specific areas. Patients will further be clinically assessed as well as undergo questionnaires.
Migraine is also a common comorbidity to visual snow syndrom and has been shown to impact similar brain regions. However, the pathophysiology is still understudied and a better understanding of the two diseases is needed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy participants |
| ||
| Patients with migraine |
| ||
| Patients with drug resistent epilepsy |
| ||
| Patients with visual snow syndrome |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Structural MRI | Diagnostic Test | We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2*-weighted sequences |
| Measure | Description | Time Frame |
|---|---|---|
| MR: multi-parameter mapping (MPM) | Once during visit 2 (1-2 weeks after visit 1) | |
| MR: quantitative susceptibility mapping (QSM) | Once during visit 2 (1-2 weeks after visit 1) | |
| Resting-state fMRI (brain and brainstem/spinal cord) | Once during visit 2 (1-2 weeks after visit 1) | |
| MR: whole-brain structural scans | Once during visit 2 (1-2 weeks after visit 1) | |
| MR: routine clinical scans | Once during visit 2 (1-2 weeks after visit 1) | |
| MR spectrosocpy | Once during visit 2 (1-2 weeks after visit 1) | |
| MR: diffusion imaging | Once during visit 2 (1-2 weeks after visit 1) | |
| MR: axial T2*w sequence | Once during visit 2 (1-2 weeks after visit 1) | |
| Task-fMRI | Once during visit 2 (1-2 weeks after visit 1) |
| Measure | Description | Time Frame |
|---|---|---|
| Migraine patients: number of migraine attacks, intensity of migraine attacks (intensity 0 - 10), duration, accompanying symptoms, Migraine diary | Once during visit 1 (1-2 weeks prior to visit 2) | |
| Migraine patients: Headache-attributed restriction, disability, social handicap and impaired participation (HARDSHIP) questionnaire |
Not provided
Inclusion Criteria:
Patients:
Healthy participants;
Exclusion Criteria:
Not provided
Not provided
The participants will be recruited from the primary care clinics as well as from referring physicians or other clinics.
Healthy controls will be recruited via public announcements and via flyers distributed at a primary care clinic and two universities.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lynn Farner, MSc | Contact | +41 44 510 72 08 | lynn.farner@balgrist.ch |
| Name | Affiliation | Role |
|---|---|---|
| Patrick Freund, Prof. Dr. med. Dr. rer. nat. | University of Zurich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Klinik Lengg | Recruiting | Zurich | 8008 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| D004827 | Epilepsy |
| C000726567 | visual snow syndrome |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D038524 | Diffusion Magnetic Resonance Imaging |
| D008279 | Magnetic Resonance Imaging |
| ID | Term |
|---|---|
| D014054 | Tomography |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
| Quantitative MRI | Diagnostic Test | We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM). |
|
| Diffusion MRI | Diagnostic Test | We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord. |
|
| fMRI | Diagnostic Test | We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord. |
|
| MR Spectroscopy | Diagnostic Test | We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord. |
|
Modified questionnaire including personal and socio-demographic, diagnostic questions related to migraine, and enquiry into headache-related burden without strict scale |
| Once during visit 1 (1-2 weeks prior to visit 2) |
| Migraine/ epilepsy/ visual snow syndrome patients: recording of possible other headache disorders and medication overuse | Once during visit 1 (1-2 weeks prior to visit 2) |
| HADS questionnaire (Hospital anxiety and depression scale) | 0-42, higher score > higher probability of anxiety/ depression | Once during visit 1 (1-2 weeks prior to visit 2) for patients and once for healthy participants at MRI visit (1-2 weeks after inclusion into study) |
| Acute medication | Once during visit 1 for patients (1-2 weeks prior to visit 2) and once for healthy participants at MRI visit (1-2 weeks after inclusion into study) |
| Epilepsy patients: diagnosis and classification according to ILAE | Once during visit 1 (1-2 weeks prior to visit 2) |
| Epilepsy patients: current anticonvulsant medication | Once during visit 1 (1-2 weeks prior to visit 2) |
| Epilepsy patients: seizure frequency | Once during visit 1 (1-2 weeks prior to visit 2) |
| Epilepsy patients: analysis of previous EEG examinations with determination of the epileptic focus (hemisphere, localization) | Once during visit 1 (1-2 weeks prior to visit 2) |
| Epilepsy patients: analysis of previous EEG examinations with qualitative assessment of the EEG to determine the type of epilepsy-specific abnormalities | Once during visit 1 (1-2 weeks prior to visit 2) |
| Migraine patients: documentation of previous therapy attempts | Which type of therapy (medication, behavioral therapy or neuromodulation) | Once during visit 1 (1-2 weeks prior to visit 2) |
| Epilepsy patients: documentation previous therapy attempts | Which type of therapy (medication, surgical intervention or neurostimulation) | Once during visit 1 (1-2 weeks prior to visit 2) |
| Visual snow syndrome: Puledda Questionnaire | The higher the score, the higher the impact of visual snow | Once during visit 2 (1-2 weeks after visit 1) |
| Migraine: Dizziness Handicap Inventory (DHI) | Score from 0-100, the higher the score, the higher the vertigo impact | Once during visit 2 (1-2 weeks after visit 1) |
| University Hospital Zurich | Recruiting | Zurich | 8091 | Switzerland |
|
| D009422 | Nervous System Diseases |